Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded by investment veterans, LYFE Capital operates from multiple locations, including the United States and Asia. The firm manages approximately $2 billion in assets under management and focuses on healthcare investments. They target critical supply chain assets and next-generation R&D services.
LYFE Capital invests in healthcare companies essential to the global value chain, targeting businesses across various medical specialties and stages of development. Their investment strategy spans pre-seed to Series C, with a particular emphasis on mature markets. Check sizes are not specified, but they aim to scale high-potential businesses into market leaders.
Notable portfolio companies include ST Pharm, a South Korean CDMO specializing in oligonucleotide synthesis with partnerships with GSK, Novartis, Roche, and BMS; Edge Medical, a China-based surgical robotic company; Profound Bio, a Seattle-based ADC platform; Bora Pharmaceuticals, a global drug development firm; Brightech, a New Jersey-based CRO; Noah Medical, specializing in endoluminal robotics; and Jeisis Medical, known for energy-based medical aesthetic devices.
Email newlp@lyfecapital.com with your deck to pitch LYFE Capital.
Yes, LYFE Capital often leads investment rounds, particularly in their focus areas within healthcare.
LYFE Capital is open to follow-on investments, especially for companies that demonstrate significant growth potential and alignment with their investment thesis.
LYFE Capital manages a fund size of approximately $2 billion, allowing them to make substantial investments across various stages.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.